Bronnen:
Traboulsee A, et al. Efficacy and safety of satralizumab monotherapy for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD): results from SAkuraStar, a double-blind placebo-controlled Phase 3 clinical study. Poster 603. ECTRIMS 2019, 11-13 sept 2019, Stockholm, Zweden.,Cree BAC, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019 Sep 5. pii: S0140-6736(19)31817-3. doi: 10.1016/S0140-6736(19)31817-3. [Epub ahead of print]
Traboulsee A, et al. Efficacy and safety of satralizumab monotherapy for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD): results from SAkuraStar, a double-blind placebo-controlled Phase 3 clinical study. Poster 603. ECTRIMS 2019, 11-13 sept 2019, Stockholm, Zweden.,Cree BAC, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019 Sep 5. pii: S0140-6736(19)31817-3. doi: 10.1016/S0140-6736(19)31817-3. [Epub ahead of print]